PDS Biotechnology
PDSB
77 hedge funds and large institutions have $16.1M invested in PDS Biotechnology in 2024 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 16 increasing their positions, 25 reducing their positions, and 20 closing their positions.
224% more call options, than puts
Call options by funds: $827K | Put options by funds: $255K
25% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 20
7% more funds holding
Funds holding: 72 → 77 (+5)
9.51% less ownership
Funds ownership: 24.51% → 15% (-9.5%)
36% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 25
47% less capital invested
Capital invested by funds: $30.2M → $16.1M (-$14.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.22M |
| 2 |
Goldman Sachs
New York
|
+$726K |
| 3 |
William Blair & Company
Chicago,
Illinois
|
+$262K |
| 4 |
AGM
Alpine Global Management
New York
|
+$240K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$159K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.42M |
| 2 |
Renaissance Technologies
New York
|
-$1.41M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.37M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$884K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$573K |
PDSB Hedge Fund Activity: Q2 2024 in Review
77 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q2 2024, worth a combined $16.1M — down 47% from $30.2M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new PDSB positions and 20 closed out — a net gain of 5 holders — while 16 added to existing stakes and 25 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.22M. The largest seller was BlackRock, cutting an estimated $4.42M.
- 77 institutional investors held PDS Biotechnology (PDSB) as of Q2 2024, up from 72 in Q1 2024.
- Funds reported $16.1M of PDS Biotechnology stock for Q2 2024, down 47% quarter-over-quarter.
- 25 funds opened new PDS Biotechnology positions in Q2 2024 and 20 closed out, a net change of +5 holders.
- The largest PDS Biotechnology buyer in Q2 2024 was Millennium Management, an estimated $1.22M added.
- The largest PDS Biotechnology seller in Q2 2024 was BlackRock, an estimated $4.42M sold.
Based on aggregated 13F filings for Q2 2024.